Comparison of clinical and serological features in thrombotic antiphospholipid syndrome patients,with and without associated systemic lupus erythematosus,followed for up to 42 years: A single centre retrospective study

Abstract

Objective

To assess the impact of concomitant systemic lupus erythematosus (SLE) on the clinicopathological manifestations of thrombotic antiphospholipid syndrome (APS).

Methods

This single-centre, retrospective study compared clinical and antiphospholipid antibody (aPL) data from 118 patients, 58 with SLE-associated APS (SLE-APS), and 60 with primary APS.

Results

Median follow-up was 13.9 (IQR 7.7–19.3) and 8.6 years (3.5–10.6) for the SLE-APS cohort and PAPS cohort, respectively. Age at diagnosis of APS was lower in the SLE-APS cohort (mean 35.9 vs PAPS: 46.7 years; p < 0.05). Distribution of aPL subtypes was similar across cohorts. 198 thrombotic events were identified overall (index plus recurrent), with venous thromboembolism (VTE) and arterial thrombosis each occurring in just over half of patients in both cohorts. Microvascular thrombosis (12.1% vs 0%), and a mixed (any combination of venous, arterial and microvascular) thrombotic phenotype (19.0% vs 6.7%, p = 0.05) were more prevalent in SLE-APS patients. Recurrent thrombosis incidence rates (∼0.5 events/10-patient years), and Kaplan-Meier recurrence-free survival after index thrombosis, were similar. In the PAPS cohort, only: (i) triple-aPL-positivity was associated with a significantly higher recurrent thrombosis event rate (incidence rate ratio 2.22, p = 0.03) and lower recurrence-free survival after first thrombosis (log-rank test p = 0.01); (ii) lupus anticoagulant (LA)-positivity was associated with higher prevalance of arterial thrombosis (RR 2.69, p = 0.01), and lower prevlance of VTE (RR 0.48, p < 0.001), versus LA-negativity.

Conclusion

Concomitant SLE does not appear to modify long-term recurrent thrombosis risk, or aPL phenotypes, in patients with APS. Triple-aPL-positivity and LA-positive status may have less influence on thrombotic outcomes in patients with SLE-APS compared to PAPS.

Keywords

Antiphospholipid syndrome systemic lupus erythematosus antiphospholipid antibodies thrombosis

Get full access to this article

View all access options for this article.

References

Cervera

Piette

Font

, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46(4): 1019–1027.

Mok

Tang

SSK

, et al. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005; 52(9): 2774–2782.

Ruiz-Irastorza

Egurbide

Ugalde

, et al. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med 2004; 164(1): 77.

Riancho-Zarrabeitia

Martínez-Taboada

Rúa-Figueroa

, et al. Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality. Lupus 2020; 29(12): 1556–1565.

Ramirez

Efthymiou

Isenberg

, et al. Under crossfire: thromboembolic risk in systemic lupus erythematosus. Rheumatology 2019; 58(6): 940–952.

Petri

Orbai

A-M

Alarcón

, et al. Derivation and validation of Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.

Miyakis

Lockshin

Atsumi

, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemostasis 2006; 4(2): 295–306.

Khawaja

Magder

Goldman

, et al. Loss of antiphospholipid antibody positivity post-thrombosis in SLE. Lupus Science & Medicine 2020; 7: e000423. DOI: 10.1136/lupus-2020-000423.

Unlu

Erkan

Barbhaiya

, et al. The impact of systemic lupus erythematosus on the clinical phenotype of antiphospholipid antibody–positive patients: results from the AntiPhospholipid syndrome alliance for clinical trials and InternatiOnal clinical database and repository. Arthritis Care Res 2019; 71(1): 134–141.

10.

Cervera

Rodríguez-Pintó

Espinosa

. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review. J Autoimmun 2018; 92: 1–11.

11.

Rosove

Brewer

. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303–308.

12.

Khamashta

Cuadrado

Mujic

, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332(15): 993–997.

13.

Arachchillage

DRJ

Efthymiou

Mackie

, et al. Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome. J Thromb Haemostasis 2014; 12(11): 1801–1809.

14.

Pengo

Ruffatti

Legnani

, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011; 118(17): 4714.

15.

Pengo

Ruffatti

Legnani

, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemostasis 2010; 8(2): 237–242.

16.

Demir

Magder

, et al. Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus. Rheumatology 2021; 60(8): 3770–3777.

17.

Barbhaiya

Zuily

Naden

, et al. The 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Arthritis Rheumatol 2023; 75(10): 1687–1702. DOI: 10.1002/art.42624.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.38 MB